The wave of AI-fueled earnings surprises that powered stocks in the last earning season will be tough to repeat, making it unlikely the results alone will spark a major rally, according to Christian Mueller-Glissmann . While companies are still likely to beat forecasts, “the bar is obviously high for this earnings season,” the head of asset allocation research at Goldman Sachs Group Inc. told Bloo...
The wave of AI-fueled earnings surprises that powered stocks in the last earning season will be tough to repeat, making it unlikely the results alone will spark a major rally, according to Christian Mueller-Glissmann . While companies are still likely to beat forecasts, “the bar is obviously high for this earnings season,” the head of asset allocation research at Goldman Sachs Group Inc. told Bloomberg Television. He added that investors will focus on companies’ outlook and executive commentary for signs that equities have room to grind higher. Goldman Sachs says consensus forecast is for S&P 500 companies to report 22% earnings growth in the second quarter, a similar figure to estimates compiled by Bloomberg Intelligence. Read More: AI Will Drive a Strong US Earnings Season, Goldman’s Snider Says “Often when you are late cycle, earnings revisions keep going for quite a long time,” Mueller-Glissmann said. “But this big, major earnings surprise wave linked to AI capex is probably closer to the end.” The biggest US tech firms are planning to spend as much as $725 billion this year on data centers, specialized chips, and networking equipment. Mueller-Glissmann said that hyperscalers are still well-positioned as they own a lot of AI infrastructure. He added that hyperscalers should start concentrating on efficiencies and monetizing AI. “The overall structural trend around AI, in our view, is intact,” Mueller-Glissmann said. Read More: S&P 500 Earnings Expectations Show Fragility: Equity Insight
RyanJLane/E+ via Getty Images In April, AWS named Twist Bioscience ( TWST ) as a wet-lab partner for Amazon Biodiscovery , its AI-powered drug-discovery application. Therapeutics revenue grew 55% reflecting the potential demand for these AI-powered tools. Twist Let’s take a step back and remember that Twist makes DNA, but perhaps the most interesting question is how it makes DNA. In the past, gene...
RyanJLane/E+ via Getty Images In April, AWS named Twist Bioscience ( TWST ) as a wet-lab partner for Amazon Biodiscovery , its AI-powered drug-discovery application. Therapeutics revenue grew 55% reflecting the potential demand for these AI-powered tools. Twist Let’s take a step back and remember that Twist makes DNA, but perhaps the most interesting question is how it makes DNA. In the past, gene synthesis was mostly done one well at a time on plastic plates. Twist miniaturized the chemistry into a silicon chip, synthesizing hundreds of thousands of unique DNA sequences in parallel. Therefore, we are talking about a semiconductor cost and scale curve applied to biology that improves as scale rises. Three businesses in a single platform The first business is DNA Synthesis and Protein Solutions . This segment just posted $53 in revenue, or 28% YoY. This has been the growth engine and the place where AI-enabled drug discovery lands. When a pharma customer wants to test thousands of antibody designs, Twist is the company that can print the library fast and at scale. Customers can enter anywhere in the design cycle, buy a pooled library or even hand Twist a target and ask for a fully managed discovery. The second business is next-generation sequencing tools , representing $57 million in the quarter (12% YoY). This is all about target enrichment and library prep chemistry that sits between the sample and the sequencer. This includes consumables-driven revenue with a strong position in diagnostics. Finally, the synthetic biology and biopharma supply of genes and constructs for industrial and pharma customers. The company’s logic is simple, rejecting one sequence in a customer’s set, the customer may route the entire order elsewhere, therefore, being able to expand by a percentage point is incremental order capture. Growth and margins inflecting together The interesting bit, and what makes the company shine is that the company is now on 13 consecutive quarters of sequentia...
AT & T is likely to lose ground to SpaceX's Starlink, putting even more pressure on shares, according to Wells Fargo. The bank initiated coverage of the telecommunications giant with an underweight rating. It also put an $18 price target on shares, implying nearly 15% downside from Tuesday's close. "We see Starlink as a near-term gainer in [broadband] vs [fixed wireless access], & longer-term disr...
AT & T is likely to lose ground to SpaceX's Starlink, putting even more pressure on shares, according to Wells Fargo. The bank initiated coverage of the telecommunications giant with an underweight rating. It also put an $18 price target on shares, implying nearly 15% downside from Tuesday's close. "We see Starlink as a near-term gainer in [broadband] vs [fixed wireless access], & longer-term disruptor to wireless," analyst Steven Cahall said in a note to clients. "Outside of T's fiber footprint we think competition will be fierce, and with weaker market share footholds excl. wireline areas we think T's wireless net adds are the most at-risk." Shares of AT & T have already fallen 15% year to date due to a variety of headwinds, including high infrastructure costs and the commoditization of telecommunications services. T YTD mountain Shares are down 15% in 2026. AT & T is also less likely than its competitors to agree to strike a mobile virtual network operator partnership with Starlink, meaning it will have to outperform on fiber and convergence to generate upside for its shares, the analyst added. Wells Fargo's call goes against consensus on Wall Street. Of the 29 analysts covering AT & T, 14 have a hold on shares, while 15 have a buy or strong buy on the stock, LSEG data shows. Shares were little changed in the premarket despite the bearish call by Wells Fargo. AT & T did not respond to CNBC's request for comment.
(RTTNews) - Industrivarden (IDVA.BE, INDU_A.ST, INDU_C.ST, IDVA.F) reported that its second quarter net income was 24.63 billion Swedish kronor compared to 1.84 billion kronor, prior year. Earnings per share was 57.03 kronor compared to 4.27 kronor.
(RTTNews) - Industrivarden (IDVA.BE, INDU_A.ST, INDU_C.ST, IDVA.F) reported that its second quarter net income was 24.63 billion Swedish kronor compared to 1.84 billion kronor, prior year. Earnings per share was 57.03 kronor compared to 4.27 kronor.
It can prove psychologically difficult to buy a stock whose price has dropped, particularly when the market has been strong. A share price drop indicates the market has concerns. Determining their validity is where an investor can make smart decisions. If the company retains a strong market share and the long-term business prospects remain bright, it's a buying opportunity. Domino's Pizza (NASDAQ:...
It can prove psychologically difficult to buy a stock whose price has dropped, particularly when the market has been strong. A share price drop indicates the market has concerns. Determining their validity is where an investor can make smart decisions. If the company retains a strong market share and the long-term business prospects remain bright, it's a buying opportunity. Domino's Pizza (NASDAQ: DPZ) is in this exact position. The share price has dropped more than 32% over the last year, through July 2. That's well below the S&P 500 's (SNPINDEX: ^GSPC) 20% gain. Continue reading
(RTTNews) - Asahi Group Holdings, Ltd. (2502.T), on Wednesday, reported its net income decreased in the full year 2025 compared with the previous year.
(RTTNews) - Asahi Group Holdings, Ltd. (2502.T), on Wednesday, reported its net income decreased in the full year 2025 compared with the previous year.
josefkubes/iStock Editorial via Getty Images My last article about Johnson & Johnson ( JNJ ) was published in October 2025. Back then, I argued that the stock was getting slowly overpriced, and I rated the stock as a “Hold” and did not see it as a great investment. In the conclusion I wrote: In my opinion, Johnson & Johnson is not the best investment right now - neither for the short-term nor for ...
josefkubes/iStock Editorial via Getty Images My last article about Johnson & Johnson ( JNJ ) was published in October 2025. Back then, I argued that the stock was getting slowly overpriced, and I rated the stock as a “Hold” and did not see it as a great investment. In the conclusion I wrote: In my opinion, Johnson & Johnson is not the best investment right now - neither for the short-term nor for the long-term. Over the long run, I see Johnson & Johnson generating "only" returns in the mid-to-high single digits, and we have to take into account the risks mentioned above, which could lower margins and profits. In the short term, I see a correction being likely, and I don't think Johnson & Johnson will be able to really break above the previous all-time high. But a lot will depend on the third-quarter results the company is reporting next week. Especially in the short term, sentiment is driving the stock market, and surprising earnings (either better or worse than expected) might drive the stock price in one way or the other. I will remain on the sidelines as I still don't see Johnson & Johnson being a good long-term investment, and other names from the pharmaceutical sector are probably better plays. While I did not consider Johnson & Johnson to be a good investment back in October 2025, the market obviously saw it differently. Since my last article was published, the stock increased 40%, and when including dividends, the total return for shareholders would have been 43%. This is without much doubt a great performance over only 9 months, and the stock clearly outperformed the S&P 500, which increased 11% in the same timeframe. On July 15, 2026, Johnson & Johnson will report second quarter results for fiscal 2026. And beforehand I will look at the company and stock once again. While we can raise the question if I was just wrong in my last article and the stock is actually a good investment, I will argue once again that Johnson & Johnson is overvalued right now and the...
Bath & Body Works (NYSE:BBWI) shares dropped 4. 1% in pre-market trading on Wednesday after Goldman Sachs downgraded the specialty retailer to Sell, citing concerns over weakening consumer sentiment, brand perception and the risks associated with its evolving distribution strategy.
Bath & Body Works (NYSE:BBWI) shares dropped 4. 1% in pre-market trading on Wednesday after Goldman Sachs downgraded the specialty retailer to Sell, citing concerns over weakening consumer sentiment, brand perception and the risks associated with its evolving distribution strategy.
SlavkoSereda/iStock via Getty Images It's time to update my thesis on Orange S.A. ( ORANY ), now about 6-7 months old, and last updated in this article here. From what I've been observing - and what you've been able to follow in my work over the past 1-2 months - there has been a growing decline in the valuation of telecommunications companies. I have highlighted this in not only giants like Deuts...
SlavkoSereda/iStock via Getty Images It's time to update my thesis on Orange S.A. ( ORANY ), now about 6-7 months old, and last updated in this article here. From what I've been observing - and what you've been able to follow in my work over the past 1-2 months - there has been a growing decline in the valuation of telecommunications companies. I have highlighted this in not only giants like Deutsche Telekom AG ( DTEGY ), but I have also mentioned companies like Finnish Elisa. While Orange has a much farther distance to fall, the French giant has also seen a significant drop in valuation, which has brought the ADR yield up to about 4.84% at the time of writing this article. Telcos have been in an interesting state for some time. Several years ago, I made many key investments - large ones - in telcos like the ones mentioned above, including also Swedish Telia, Norwegian/Swedish Telenor, and Tele2. At the time, over 15% of my entire portfolio was actually in telecommunications - today it's still less than 4% because I sold most of it when the sector went into overvaluation. Telecommunication companies are businesses that operate in cycles - and the cycles are tied to spending (CapEx), usually in turn related either to spectrum/infrastructure or marketing/expansion. Preferably, they are companies that are relatively simple and don't try to “stray” outside their typical field, meaning wireless/cable internet and phone communications. There are exceptions - my recent article on Rogers Communications Inc. ( RCI ) shows us that there are companies that, despite including things like media and programming, can do well (at times), if bought at the right valuation, and if the media wasn't added to it as sort of a tack-on hope (at least that's how I view it, as what differs it from the whole AT&T/TimeWarner debacle). In my last article, I made a case for Orange being too highly valued for the company's mix of political, earnings, and forecast risks. The company proceeded to go...